Anavex Life Sciences receives US patent for ANAVEX 2-73 (blarcamesine)

Anavex Life Sciences has secured new US intellectual property compositions patent for its ANAVEX 2-73 (blarcamesine). The patent number 11,661,405 has …

Swiss company Lonza acquires Synaffix to boost ADC offering

Switzerland-based company Lonza has boosted its antibody-drug conjugates (ADCs) offering with the acquisition of Dutch biotechnology company Synaffix for a …

Rentschler Biopharma and Ikarovec partner to expedite new gene therapies

Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease. Under the deal, Rentschler Biopharma’s …

China’s NMPA approves Vascepa for hypertriglyceridemia

China’s National Medical Products Administration (NMPA) has granted regulatory approval to Amarin’s commercial partner EddingPharm (EDDING) for Vascepa (icosapent ethyl). Vascepa …

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Sanofi has announced that its anti-CD40L antibody frexalimab demonstrated significantly reduced disease activity in a Phase II trial of patients …